roflumilast


( Last Updated : January 4, 2023)
Generic Name:
roflumilast
Project Status:
Pending
Therapeutic Area:
Plaque psoriasis
Manufacturer:
Arcutis Biotherapeutics, Inc.
Call for patient/clinician input open:
Brand Name:
Zoryve
Project Line:
Reimbursement Review
Project Number:
SR0771-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
​ZORYVE™ (roflumilast cream, 0.3%) is indicated for topical treatment of plaque psoriasis, including treatment of psoriasis in the intertriginous areas, in patients 12 years of age and older.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​ZORYVE™ (roflumilast cream, 0.3%) is indicated for topical treatment of plaque psoriasis, including treatment of psoriasis in the intertriginous areas, in patients 12 years of age and older.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.